Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

Press/Media: Press / Media

PeriodOct 2 2018

Media coverage

1

Media coverage

  • TitleOral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
    Media name/outletClinical Trials.gov
    CountryUnited States
    Date10/2/18
    PersonsTyler J Curiel